Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
October 15, 2019
Assignee:
DUPONT US HOLDING, LLC
Inventors:
Scott Christopher Jackson, Leo Ernest Manzer, Henry Max Schleinitz, Mark A Scialdone, Keith W Hutchenson
Abstract: An organic photovoltaic device includes an anode and a cathode. The organic photovoltaic device includes an active layer between the anode and the cathode. The active layer includes a p-type material. The p-type material includes a donor-acceptor (DA) polymer. An acceptor unit of the DA polymer includes a functionalized pyranopyran-dione compound or a functionalized naphthyridine-dione compound.
Type:
Grant
Filed:
October 18, 2017
Date of Patent:
February 19, 2019
Assignee:
International Business Machines Corporation
Abstract: This invention provides a novel non-natural pharmaceutical compound having a different mechanism than statin drugs and having a selective inhibitory activity against ACAT2.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
February 20, 2018
Assignee:
School Juridical Person Kitasato Institute
Abstract: Disclosed are methods for treating catmint oil. The process allows the separation of sulfur-containing compounds from the catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Grant
Filed:
June 5, 2015
Date of Patent:
June 27, 2017
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
Scott Christopher Jackson, Leo Ernest Manzer, Henry Max Schleinitz, Mark A Scialdone, Keith W Hutchenson
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone, and from which formulated products may be prepared.
Type:
Grant
Filed:
September 24, 2013
Date of Patent:
December 20, 2016
Assignee:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
John Charles Fisher, Keith W Hutchenson, Scott Christopher Jackson, Leo Ernest Manzer, Mark A Scialdone, Mayis Seapan
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone, and from which formulated products may be prepared.
Type:
Application
Filed:
September 24, 2013
Publication date:
March 26, 2015
Applicant:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
JOHN CHARLES FISHER, KEITH W. HUTCHENSON, SCOTT CHRISTOPHER JACKSON, LEO ERNEST MANZER, MARK A. SCIALDONE, MAYIS SEAPAN
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Grant
Filed:
September 24, 2013
Date of Patent:
February 10, 2015
Assignee:
E I du Pont de Nemours and Company
Inventors:
Scott Christopher Jackson, Leo Ernest Manzer, Henry Max Schleinitz, Mark A Scialdone, Keith W Hutchenson
Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.
Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
Abstract: The present invention relates to the compounds useful in the prevention and/or treatment of tumors. More specifically the present invention relates to inhibitors of the activity of the electron transport chains and/or the mitochondrial TCA cycle in glioma-initiating cells (GICs) for use in a method for preventing and/or treating tumors presenting glioma-initiating cells (GICs) in a subject who has undergone a prior removal of a tumor glioma bulk. The present invention further provides a pharmaceutical composition containing the inhibitors of the invention and a screening method for identifying the inhibitors of the invention.
Type:
Grant
Filed:
May 20, 2010
Date of Patent:
August 26, 2014
Assignees:
Universite de Geneve, Hopitaux Universitaires de Geneve
Abstract: A method for converting trans-cis nepetalactone to cis-trans nepetalactone using molecular sieves. The molecular sieves may, for example, have a pH in water of at least about 9, and/or may be activated prior to use by heating.
Abstract: This invention provides a process for producing dihydronepetalactone using mixtures comprising both trans-cis nepetalactone and cis-trans nepetalactone. A reaction mixture comprising trans-cis nepetalactone and cis-trans nepetalactone is first contacted with hydrogen in the presence of at least one hydrogenation catalyst under conditions that optimise the preferential conversion of trans-cis nepetalactone to dihydronepetalactone. Cis-trans nepetalactone is subsequently converted to dihydronepetalactone by contact with hydrogen in the presence of at least one hydrogenation catalyst.
Type:
Grant
Filed:
December 20, 2007
Date of Patent:
July 1, 2014
Assignee:
E I du Pont de Nemours and Company
Inventors:
Keith W. Hutchenson, Scott Christopher Jackson, Leo Ernest Manzer, Mark A. Scialdone, Mayis Seapan
Abstract: The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells. The present invention relates to the use of N-(9-acridinyl)maleimide (NAM) or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species (e.g., sulphur-containing species) present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead) cells. The present invention also relates to the use of NAM or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species present in intact and/or non-intact cells. Moreover, the present invention relates to the use of measuring techniques and/or instruments coupled with the use of NAM or with the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI).
Type:
Grant
Filed:
July 14, 2009
Date of Patent:
April 15, 2014
Assignee:
ChemoMetec A/S
Inventors:
Mette Elena Skindersø, Helle Frobøse Sørensen, Søren Kjaerulff
Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.
Type:
Grant
Filed:
December 13, 2010
Date of Patent:
March 25, 2014
Assignee:
Nono Inc.
Inventors:
Xiujun Sun, Michael Tymianski, Jonathan David Garman
Abstract: Dihydronepetalactone, a minor natural constituent of the essential oil of catmints (Nepeta spp.) such as Nepeta cataria, has been identified as an effective insect repellent compound. Synthesis of dihydronepetalactone may be achieved by hydrogenation of nepetalactone, the major constituent of catmint essential oils. This compound, which also has fragrance properties, may be used commercially for its insect repellent properties, and methods for making an composition thereof are disclosed.
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Application
Filed:
September 24, 2013
Publication date:
January 16, 2014
Applicant:
E I DU PONT DE NEMOURS AND COMPANY
Inventors:
SCOTT CHRISTOPHER JACKSON, LEO ERNEST MANZER, HENRY MAX SCHLEINITZ, MARK A. SCIALDONE, KEITH W. HUTCHENSON
Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (polymer stabilized) or PSA (polymer sustained alignment) type.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
November 26, 2013
Assignee:
Merck Patent GmbH
Inventors:
Achim Goetz, Erdal Durmaz, Malgorzata Rillich, Andreas Taugerbeck
Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.
Type:
Application
Filed:
December 27, 2011
Publication date:
November 21, 2013
Applicant:
Merck Patent GmbH
Inventors:
Andreas Taugerbeck, Achim Goetz, Alexander Hahn, Martin Engel
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone, and from which formulated products may be prepared.
Type:
Grant
Filed:
December 20, 2007
Date of Patent:
October 15, 2013
Assignee:
E I du Pont de Nemours and Company
Inventors:
John Charles Fisher, Keith W. Hutchenson, Scott Christopher Jackson, Leo Ernest Manzer, Mark A. Scialdone, Mayis Seapan
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Grant
Filed:
December 20, 2007
Date of Patent:
October 8, 2013
Assignee:
E I du Pont de Nemours and Company
Inventors:
Scott Christopher Jackson, Leo Ernest Manzer, Henry Max Schleinitz, Mark A. Scialdone, Keith W. Hutchenson
Abstract: Compounds which directly inhibit IRE-1? activity in vitro, prodrugs, and pharmaceutically acceptable salts there-of. Such compounds and prodrugs are useful for treating diseases associated with the unfolded protein response or with regulated IRE1-dependent decay (RIDD) and can be used as single agents or in combination therapies.
Type:
Application
Filed:
April 5, 2011
Publication date:
May 9, 2013
Applicant:
MANNKIND CORPORATION
Inventors:
Qingping Zeng, Andras Toro, John Bruce Patterson, Warren Stanfield Wade, Zoltan Zubovics, Yun Yang, Zhipeng Wu
Abstract: This invention relates to novel coumarin derivatives, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents. This invention also relates to novel methods for modeling and/or predicting the repellency of unknown compounds.
Type:
Application
Filed:
September 21, 2012
Publication date:
March 28, 2013
Applicants:
CNRS (CENTRE NATIONAL RECHERCHE SCIENTIFIQUE), MERIAL LIMITED
Inventors:
Jean Delaveau, Pierre Nicolas Stebe, Nathalie Marchand-Geneste
Abstract: A photoelectric conversion material is provided and includes an organic material having an absorbing coefficient of about 1.5×105 (cm?1) or more and that is represented by the following formula (1). In the formula (1), each of R1 to R20, and each of X1 to X8 is one of a hydrogen atom and a substituent.
Abstract: This invention relates to novel coumarin derivative, formulations comprising same, and to methods of making and using these compounds and formulations, which are useful as repellents against insects and/or pests. The compounds also prevent illness and disease caused by insect/pest-borne vectors, and provide safer, more effective alternatives to existing repellents.
Type:
Application
Filed:
June 21, 2012
Publication date:
December 27, 2012
Inventors:
Jean Delaveau, Emile Vialle, Marc Lemaire, Stephane Pellet-Rostaing, Bruno Andrioletti
Abstract: The present invention relates to novel coumarin derivatives, their carboxamides, pharmaceutical compositions containing them and their uses as drugs for kidney protection, treating drugs of hypertension, cardio-cerebrovascular diseases, non-insulin dependent diabetes, tumor, pre-cancerous lesion, and edemas.
Type:
Grant
Filed:
December 5, 2003
Date of Patent:
December 25, 2012
Assignee:
Institute of Materia Medica Chinese Academy of Medical Sciences
Inventors:
Shiping Xu, Xiaoguang Chen, Song Xu, Lanmin Li, Longfei Xie, Hongyan Li, Yan Li, Guifang Cheng
Abstract: The present invention provides a compound having absorbing and luminescence wavelengths at relatively longer wavelength side of the visible area, and having thermal stability, which acts as a dye and/or a luminescence material and has practical utility therefor, and a production method thereof.
Abstract: Compositions are provided in which dendrimers and/or nanoparticles are synthesized with multi-photon responsive elements and self-immolative oligomers. The compositions may be utilized to selectively deliver Payloads within tissue by irradiating the compositions. The compositions may also be used to amplify sensitivity to irradiation.
Type:
Application
Filed:
September 23, 2010
Publication date:
October 11, 2012
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: Dibenzylidene and heterobenzylideneacetone derivatives, related 4-piperidones, related 4-thiopyranones and the corresponding sulfinyl- and sulfonyl-analogues for their use for prophylaxis or treatment of trypanosomiasis and leishmaniasis.
Type:
Application
Filed:
September 20, 2010
Publication date:
August 23, 2012
Applicant:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Inventors:
Elisabeth Davioud-Charvet, Ingrid Nicole Wenzel, Thomas J.J. Muller, Gilles Hanquet, Don Antoine Lanfranchi, Frederic Leroux, Thibault Gendron
Abstract: The invention relates to methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid (1,3PDS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 1,3PDS, either in vitro or in vivo. The invention also relates to sulfonate ester prodrugs of 1,3PDS as well as Gemini dimmers and oligomers of 1,3PDS for the prevention or treatment of associated diseases and conditions.
Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.
Type:
Application
Filed:
August 30, 2010
Publication date:
July 19, 2012
Applicant:
MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
Abstract: Antimicrobial compounds from Epicoccum purpurascens (syn. E. negrum) for use against plant and fungi pathogens. An orange yellow metabolite was isolated, the structure elucidated as a small group of compounds Epipyrone A-C and fungicidal activity demonstrated against plant pathogens, for example Botrytis cinerea and Lecanicillium muscarium. Agricultural and pharmaceutical compositions are provide, and use thereof in treating microbial infections in an animal or plant are also provided.
Type:
Application
Filed:
August 24, 2011
Publication date:
May 3, 2012
Inventors:
Roel van Ginkel, Andrew Ian Selwood, Alistair Lawrence Wilkins, Stephen Ford, Cody Calder
Abstract: The present invention provides simple, rapid methods and procedures for analyzing cells, hereunder quantitative and qualitative assessment of cells. The present invention relates to the use of N-(9-acridinyl)maleimide (NAM) or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species (e.g., sulphur-containing species) present in higher concentrations in intact (e.g., living) cells than in non-intact (e.g., dead) cells. The present invention also relates to the use of NAM or to the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI), particularly detectable upon its reaction with species present in intact and/or non-intact cells. Moreover, the present invention relates to the use of measuring techniques and/or instruments coupled with the use of NAM or with the use of 7-diethylamino-3-((4?-(iodoacetyl)amino)phenyl)-4-methylcoumarin (CPI).
Type:
Application
Filed:
July 14, 2009
Publication date:
December 22, 2011
Applicant:
CHEMOMETEC A/S
Inventors:
Mette Elena Skindersø, Helle Frobøse Sørensen, Søren Kjærulff
Abstract: The present invention is directed to coumarin derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to ion channels such as potassium channels.
Abstract: Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
Abstract: The present invention relates to a photolabile compound including a coumarin family caging group covalently bound to an organic moiety containing a carboxyl group, an amino group, a sulfhydryl group, and/or a hydroxyl group. The photolabile compound, upon absorbing visible light, releases the organic moiety. Also disclosed is a method of making a photolabile compound that releases a biologically active compound upon absorbing visible light by providing an organic moiety and binding a coumarin family caging group to the organic moiety under conditions effective to make the photolabile compound. The present invention also relates to a method of obtaining a biologically active compound in a sample. The method involves adding to a sample a photolabile compound including a coumarin family caging group covalently bound to an organic moiety. The sample is then illuminated with visible light under conditions effective to obtain a biologically active compound including the organic moiety.
Type:
Grant
Filed:
April 12, 2006
Date of Patent:
November 8, 2011
Assignee:
Cornell Research Foundation, Inc.
Inventors:
George P. Hess, Barry K. Carpenter, Vishakha R. Shembekar, Yongli Chen
Abstract: The present invention relates to 3,4-disubstituted coumarin and quinolone derivatives and processes for their preparation. The invention also related to methods for treating infection of Hepatitis C virus by administering a 3,4-disubstituted coumarin or quinolone derivative.
Type:
Grant
Filed:
March 29, 2005
Date of Patent:
November 1, 2011
Assignee:
XTL Biopharmaceuticals Ltd.
Inventors:
Bin Xu, Qiang Zhu, Hyun-Joon Cho, Reza Fathi, Zhen Yang, Anthony Sandrasagra, Yixin Liu
Abstract: This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.
Type:
Application
Filed:
December 13, 2010
Publication date:
October 13, 2011
Applicant:
NoNO, Inc.
Inventors:
Xiujun Sun, Michael Tymianski, Jonathan David Garman
Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (polymer stabilised) or PSA (polymer sustained alignment) type.
Type:
Application
Filed:
September 29, 2009
Publication date:
August 25, 2011
Applicant:
MERCH PATENT GESELLSCHAFT MIT BESCHRANKTE HAFTUNG
Inventors:
Achim Goetz, Erdal Durmaz, Malgorzata Rillich, Andreas Taugerbeck
Abstract: The present invention provides a compound having absorbing and luminescence wavelengths at relatively longer wavelength side of the visible area, and having thermal stability, which acts as a dye and/or a luminescence material and has practical utility therefor, and a production method thereof.
Abstract: The present invention relates to a heterocycle-containing onium salt useful as, for example, a cationic photopolymerization initiator and an acid generator for a chemically amplified resist, and provides a heterocycle-containing onium salt shown in the specification.
Abstract: The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.
Abstract: A method for converting trans-cis nepetalactone to cis-trans nepetalactone using molecular sieves. The molecular sieves may, for example, have a pH in water of at least about 9, and/or may be activated prior to use by heating.
Abstract: A functionalized polycyclic compound can have a structure of Formula 1 or salt, prodrug, analog, or derivative thereof, which compound can be prepared by providing a diene; reacting the diene with a dienophile under sufficient conditions for a combined Diels-Alder/acylation reaction so as to provide a polycyclic compound having a carboxylic acid; and coupling the carboxylic acid with an amine-containing compound or a hydroxyl-containing compound so as to form an amide or an ester and producing a compound having a structure of Formula 1. The compound can be used for modulating an opioid receptor, which can be conducted by administering to an opioid receptor a functionalized polycyclic compound as described herein in an effective amount to modulate the functionality of the opioid receptor. Such opioid modulation can provide a biological benefit to a subject.
Type:
Application
Filed:
September 25, 2009
Publication date:
October 7, 2010
Inventors:
Jeffrey Aube, Bryan L. Roth, Partha Ghosh, Kevin J. Frankowski
Abstract: A process for preparation of 4-hydroxy-pyran-2-one derivative of formula (I), wherein R is, and wherein R1 and R2 are methyl and R3 is hydrogen or methyl, comprising the steps of, heating a compound of formula (II), wherein R is as defined before, and R4 is hydrogen, NH4+ or an alkali metal, in a solvent mixture consisting of an aromatic hydrocarbon and a ketone in an inert atmosphere at a temperature of between 60° C. to 92° C. in the absence or presence of orthophosphoric acid or its alkali dihydrogen salts or alkali hydrogen salts of a dibasic acid, followed by optional neutralization of the reaction mixture with an organic base and obtaining compound of formula (I) in high purity and substantially free of impurities through a step of isolation and crystallization. The process leads to formation of derivatives of formula I in high purity with dimmer impurity (III) less than 0.1% and anhydro impurity (IV) below 0.15%.
Abstract: This invention provides a process for producing dihydronepetalactone using mixtures comprising both trans-cis nepetalactone and cis-trans nepetalactone. A reaction mixture comprising trans-cis nepetalactone and cis-trans nepetalactone is first contacted with hydrogen in the presence of at least one hydrogenation catalyst under conditions that optimise the preferential conversion of trans-cis nepetalactone to dihydronepetalactone. Cis-trans nepetalactone is subsequently converted to dihydronepetalactone by contact with hydrogen in the presence of at least one hydrogenation catalyst.
Type:
Application
Filed:
December 20, 2007
Publication date:
July 1, 2010
Applicant:
E.I. DU PONT DE NEMOURS AND COMPANY
Inventors:
Keith W. Hutchenson, Ccott Christopher Jackson, Leo Ernest Manzer, Mark A. Scialdone, Mayis Seapan
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone, and from which formulated products may be prepared.
Type:
Application
Filed:
December 20, 2007
Publication date:
June 10, 2010
Applicant:
E.I. DU PONT DE NEMOURS AND COMPANY
Inventors:
John Charles Fisher, Keith W. Hutchenson, Scott Chirstopher Jackson, Leo Ernest Manzer, Mark A. Scialdone, Mayis Seapan
Abstract: Disclosed are methods for treating catmint oil. The treated catmint oil can be used for the production of hydrogenated catmint oil, which is enriched in the insect repellent, dihydronepetalactone.
Type:
Application
Filed:
December 20, 2007
Publication date:
June 10, 2010
Applicant:
E. I. DU PONT DE NEMOURS AND COMPANY
Inventors:
Scott Christopher Jackson, Leo Ernest Manzer, Henry Max Schleinitz, Mark A. Scialdone